alexa Fibromyalgia And Chronic Fatigue Syndrome (CFS): Translational Biomarkers As Applicable To Monitor And To Predict Clinical Manifestations
ISSN: 2153-0645

Journal of Pharmacogenomics & Pharmacoproteomics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

2nd International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics
November 03-05, 2014 Embassy Suites Las Vegas, USA

Kirill Shlyapnikov
ScientificTracks Abstracts: J Pharmacogenomics Pharmacoproteomics
DOI: 10.4172/2153-0645.S1.002
Abstract
Сurrently there is no clear understanding of the CFS and FM pathogenesis, therefore there are no clear criteria and their biomarkers. Due to the lack of objective criteria, CFS and FM have not been recognized as nosology for a long time. In the course of clinical research and observation of this group of patients we have found a number of patterns. For assessment by the severity scale and the choice of therapy, we have developed and use integrated biomarker of CFS/FM severity. Here we used our experience, the psychometric testing data and treatment terms and results statistics. In particular, we use 4 main biomarkers of CFS and FM: Compliance of the clinical presentation to the conventional CFS and FM criteria, REM sleep deficiency, increase of percentage of CD19, CD5 cells to the total CD19 population, producing the herpes group viruses DNA (HSV, EBV, CMV, HHV6) with saliva and urine, PCR or serological evidence of infection with chlamydia, mycoplasma, viral hepatitis B, C, D, G, TT, borrellia, yersinia, beta- hemolytic streptococcus of group A. We have created and used ?three in one? method of prevention and treating CFS and fibromyalgia. Method shows the possibility of successful prevention of fibromyalgia in predisposed persons. Stage-by-stage control of the treatment efficiency shows a steady decline or absence of pain syndrome, and positive dynamics by the scale of integrated biomarker of CFS/MF severity. In 38% of cases we can talk about clinical recovery in 6 months.
Biography
Kirill Shlyapnikov, MD, Neurologist, Clinical Immunologist, obtained neurology specialization at Moscow State Medical-Stomatological University (MSMSU) and then immunology specialization at Peoples? Friendship University of Russia (PFUR). Research activities cover clinical aspects of chronic fatigue syndrome and fibromyalgia, autoimmune diseases of the nervous system and neuroinfections. He is Founder and Director of a private clinic ?Echinacea? in Moscow.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords